Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

By F. Cosman, D. Crittenden, J. Adachi, N. Binkley, E. Czerwiński, S. Ferrari, L. Hofbauer, E. Lau, E. Lewiecki, A. Miyauchi and 7 more. New England Journal of Medicine, 2016

1,423 citations recorded by the source corpus.

Subfields: Molecular Biology, Orthopedics and Sports Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/b06d845c8a688ac5ad09e4debe8598b8fc395926

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Hans Clevers
2. R. Nusse
3. Elaine Fuchs
4. C. Blanpain
5. Xi He
6. M. Resh
7. S. Angers
8. Jessica Rios-Esteves

Citations in the corpus

• Wnt/ b -Catenin Signaling, Disease, and Emerging Therapeutic Modalities (2017, background): “This suggests that blocking SOST would only impact on bone (Jawad et al., 2013), and indeed, an antibody targeting SOST, known under the brand name Romosozumab, has yielded encouraging results in clinical trials (Cosman et al., 2016).”
• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Follow-on therapy with denosumab and, to a lesser degree, alendronate preserve or continue to accrue BMD benefits following romosozumab therapy [196, 198, 199].”